Impact Analysis of Covid-19
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
Humira (adalimumab) is a tumor necrosis factor (TNF) blocker that reduces the effects of a substance in the body that can cause inflammation.
Humira is used to treat many inflammatory conditions in adults, such as ulcerative colitis, Rheumatoid Arthritis, psoriatic arthritis, Ankylosing Spondylitis, plaque psoriasis, and a skin condition called hidradenitis suppurativa.
Humira is also used in adults and children to treat Crohn's disease or juvenile idiopathic arthritis.
Scope of the Report:
Humira is widely used for Ankylosing Spondylitis, Rheumatoid Arthritis, Crohn's disease and other disease. The most proportion of Humira is for Ankylosing Spondylitis, and the proportion in 2017 is about 43%, and the proportion is in decreasing trend from 2013 to 2017.
USA is the largest market, with a sales market share nearly 65% in 2017. Following USA, Europe is the second largest market with the sales market share of 30%.
The worldwide market for Humira is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2024, from xx million US$ in 2019, according to a new WMR study.
This report focuses on the Humira in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
Market Segment by Manufacturers, this report covers
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Market Segment by Applications, can be divided into
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Humira product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Humira, with price, sales, revenue and global market share of Humira in 2017 and 2018.
Chapter 3, the Humira competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Humira breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2014 to 2019.
Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2014 to 2019.
Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2014 to 2019.
Chapter 12, Humira market forecast, by regions, type and application, with sales and revenue, from 2019 to 2024.
Chapter 13, 14 and 15, to describe Humira sales channel, distributors, customers, research findings and conclusion, appendix and data source.